Home Blog Page 1275

Panduit Strengthens Commitment to Customer Excellence with Appointment of Holly Garcia to Chief Commercial Officer

By
Advertorial Desk
-

SINGAPORE, Jan. 16, 2026 /PRNewswire/ — Panduit, a global leader in electrical and network infrastructure solutions, announced the promotion of Holly Garcia to Chief Commercial Officer on 13 January 2026. In this role, Garcia will lead the company’s global commercial strategy, focusing on the company’s commitment to innovation and delivering a best-in-class experience for customers. Garcia will report directly to Panduit President, Marc Naese.

“Holly has the vision and expertise to position our company for continued growth and success while deepening our customer relationships,” said Naese. “Holly’s leadership as Chief Commercial Officer will be instrumental in strengthening the customer experience and delivering the value our markets expect.”

In her most recent role as Vice President of Panduit’s Data Center business unit, Garcia spearheaded global growth and innovation initiatives. She led the development of business strategy and directed new product introductions to strengthen Panduit’s position in the rapidly evolving data center market. With more than 25 years of experience in sales, marketing, and business unit leadership, Garcia brings a proven track record of driving commercial success and transformative growth.

“I’m honored to take on the role of Chief Commercial Officer and excited to lead our commercial strategy during this time of growth,” explained Garcia. “Our team’s commitment to innovation and customer success has positioned us as a trusted partner globally, and I look forward to driving even greater value for our customers and stakeholders.”

About Panduit

Panduit is a leading global manufacturer of high-quality electrical and network infrastructure and connectivity solutions. Operating from our headquarters in Tinley Park, Ill., USA, and across 112 worldwide locations, we drive innovation through strategic R&D investments and breakthrough product development while providing seamless global support and service. Since 1955, our commitment to our customers and partners has remained constant. And together, with them, we create exceptional solutions that support their businesses in a way that’s good for them and good for the world. Panduit is making the connections that matter. For more information, visit www.panduit.com.

YTTEK joins Taiwan’s national B5G LEO satellite program, accelerating indigenous space communications

By
Advertorial Desk
-

HSINCHU, Jan. 16, 2026 /PRNewswire/ — YTTEK, a leading provider of wireless communication solutions, has been awarded a crucial contract by the Taiwan Space Agency (TASA) to develop the core communications payload for Taiwan’s ambitious Beyond 5G (B5G) Low Earth Orbit (LEO) satellite initiative. Since the contract award in June 2025, the project has progressed steadily and has now entered the engineering verification phase.

The contract, officially titled “Pathfinder Communication Payload Baseband Module Prototype Development,” positions YTTEK at the forefront of the nation’s push for space communication autonomy. YTTEK will leverage its core expertise in Software-Defined Radio (SDR) technology to design, implement, and verify the fundamental components of the first domestically developed LEO satellite payload.

SDR at the core: Building the next-generation communications payload
TASA’s B5G satellite initiative includes two experimental LEO spacecraft. The first payload (1A) was contracted to U.S.-based CesiumAstro, while the 1B satellite—designed to showcase Taiwan’s indigenous aerospace capabilities—will be developed domestically.

TASA will lead the 1B payload development in collaboration with top Taiwanese companies, including YTTEK, and research institutions.

“We are honored to join TASA’s national space team,” said Jiangson Chen, CEO of YTTEK. “YTTEK will apply its deep experience in SDR system design to deliver a high-integration, high-value wireless communications payload that advances Taiwan’s autonomy in LEO satellite technology.”

Strengthening Taiwan’s space manufacturing and B5G competitiveness
The B5G experimental satellite program serves two missions: Technology validation and building Taiwan’s domestic space supply chain. The Taiwan-developed 1B satellite is scheduled to launch in 2030. YTTEK’s participation highlights the country’s commitment to establishing a resilient and fully local communications payload ecosystem.

As the Pathfinder phase of the 1B communications payload program formally enters the engineering verification stage, YTTEK’s participation underscores Taiwan’s commitment to building a resilient, fully indigenous communications payload ecosystem and strengthening its competitiveness in the global B5G landscape.

Proven reliability: Validated by TASA missions
YTTEK specializes in SDR-based wireless communication-modules for satellites and defense-grade Unmanned Aerial Vehicles (UAVs). The company’s HyperSDR satellite ground station modem has already demonstrated space-grade reliability by successfully receiving and decoding signals from TASA’s Formosat-5 and NASA’s Landsat-8 and Landsat-9 satellites.

Building on these proven capabilities, YTTEK’s participation in the Pathfinder payload program further extends its experience from ground-based systems to spaceborne communications payloads.

About YTTEK Technology
YTTEK, a leader in Software-Defined Radio (SDR), delivers cutting-edge wireless communication solutions for satellite communications, defense UAV and academia applications. We are dedicated to offering proven, reliable, and integrated communication solutions, helping customers accelerate product development and ensure exceptional performance.

For more information, please visit https://yttek.com/solutions/satcom/.

MindHYVE.ai™ and The Open University of Kenya Announce Strategic Collaboration on AI-Powered Learning and Academic Innovation

By
Advertorial Desk
-

NAIROBI, Kenya and NEWPORT BEACH, Calif., Jan. 16, 2026 /PRNewswire/ — The Open University of Kenya (OUK) and MindHYVE.ai, Inc., a U.S.-based artificial intelligence company, have signed a Memorandum of Understanding (MoU) establishing a strategic collaboration focused on advancing AI-powered learning enablement and academic innovation.

A new chapter in digital education: MindHYVE.ai™ and The Open University of Kenya unite to pioneer AI-driven learning
A new chapter in digital education: MindHYVE.ai™ and The Open University of Kenya unite to pioneer AI-driven learning

The collaboration explores the integration of ArthurAI™, MindHYVE.ai’s proprietary agentic artificial intelligence system, into selected areas of OUK’s digital learning ecosystem. The initiative is designed to support personalized learning, faculty enablement, data-driven curriculum innovation and workforce-aligned upskilling, positioning OUK as a leader in next-generation digital education across Africa.

Under the MoU, the parties will jointly explore implementation of ArthurAI as a virtual academic enabler, supporting learners and educators through adaptive, real-time learning assistance. The collaboration also includes curriculum co-design, impact evaluation, localization aligned with Kenya’s education policy and adherence to the Kenya Data Protection Act (2019).

“This collaboration reflects the Open University of Kenya’s commitment to innovation, access and academic excellence,” said Professor Elijah Omwenga, Vice-Chancellor of the Open University of Kenya. “By exploring responsible AI-powered learning systems, we aim to enhance student success, empower faculty and strengthen Kenya’s position as a digital education leader.”

“OUK represents a bold and forward-looking model for higher education in the digital age,” said Bill Faruki, Founder and CEO at MindHYVE.ai™. “This collaboration allows us to responsibly explore how agentic AI can support learning, teaching and workforce readiness—while maintaining transparency, ethics and local relevance.”

This collaboration reflects a shared vision to advance responsible AI in education, expand access to high-quality digital learning and support Kenya’s broader goals for workforce development and innovation.

About The Open University of Kenya

The Open University of Kenya (OUK), established by Charter in August 2023, is Kenya’s first fully online specialised public University. OUK is mandated to expand access to affordable, flexible, self-paced, inclusive and high-quality higher education through digital and open learning innovation. It offers Professional Development Courses, Undergraduate and Postgraduate Programmes designed to meet the needs of learners across Kenya and beyond.

Website: https://ouk.ac.ke/ ∕ Email: info@ouk.ac.ke ∕ Contact: +254 703 211 211

Media Contact:
Brendah Kabindio
Email: bkabindio@ouk.ac.ke

About MindHYVE.ai™

MindHYVE.ai™ is redefining the boundaries of intelligence by engineering autonomous systems and deploying domain-specific AGI agents across real-world sectors. Powered by the Ava-Fusion™ large reasoning model and architected for agent coordination, swarm intelligence, and adaptive autonomy, MindHYVE’s technology stack is revolutionizing law, medicine, finance, education, and governance.

With operations in North America, Asia, and Africa, MindHYVE.ai™ is on a mission to democratize access to transformative intelligence and architect the infrastructure for post-scarcity economies. Backed by HYVE Labs, the company continues to shape the future of agentic systems on a global scale.

Website: www.mindhyve.ai | Email: hello@mindhyve.io | Contact: +1 (949) 200-8668

Media Contact:
Marc Ortiz
Email: marc.ortiz@mindhyve.io

Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs

By
Advertorial Desk
-

SHANGHAI and HONG KONG, Jan. 16, 2026 /PRNewswire/ — Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plans for its core clinical asset, ATG-022 (a CLDN18.2 antibody-drug conjugate [ADC]), as well as R&D progress on ATG-125 (a B7-H3 x PD-L1 bispecific ADC), its steric hindrance masking AnTenGager™ T cell engager (TCE) platform, and other key preclinical programs.

1. Core Clinical Program: ATG-022

  • Latest data from the Phase I/II CLINCH study: As of December 25, 2025, among patients with moderate to high CLDN18.2 expression (IHC 2+ > 20%) in the 2.4 mg/kg dose cohort, the objective response rate (ORR) was 40% (12/30) and the disease control rate (DCR) was 90% (27/30), with a median progression-free survival (mPFS) of 5.09 months and a median overall survival (mOS) of 14.72 months. In the 1.8 mg/kg dose cohort, the ORR was 46.7% (14/30), the DCR was 86.7% (26/30), the mPFS was 6.97 months, and the mOS has not yet been reached. Among patients with low/ultra-low CLDN18.2 expression (IHC 2+ ≤ 20%) treated at the efficacious dose range of 1.8-2.4 mg/kg, the ORR was 28.6% (6/21). In addition, one patient in each of the three dose groups achieved a complete response (CR). These results demonstrated the potent anti-tumor activity of ATG-022 across all levels of CLDN18.2 expression.
  • Promising frontline combination potential: Compared with the data presented at the Company’s R&D Day in November last year, the 1.8 mg/kg dose group demonstrated afurther improvement in ORR and a meaningful prolongation in mPFS, while maintaining a favorable safety profile. The incidence of Grade 3 or higher treatment-related adverse events (TRAEs) was only 19.4%. This differentiated safety profile positions ATG-022 as a potentially best-in-class ADC in terms of safety, with the potential to be combined with checkpoint inhibitors (CPIs) and chemotherapy to transform the current frontline standard-of-care regimen.
  • First Disclosure of Positive Clinical Signals of ATG-022 in Non-Gastrointestinal Tumors: As of January 6, 2025, among 9 efficacy evaluable patients, the ORR was 22.2% (2/9), and DCR was 88.9% (8/9). These data suggest that ATG-022 may have the potential to treat CLDN18.2-positive non-gastrointestinal tumors, which could expand the treatable patient population beyond gastrointestinal cancers. The efficacy observed to date also supports further exploration of CLDN18.2 as a pan-tumor therapeutic target.
  • Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase I/II CLINCH study and the Phase Ib/II CLINCH-2 study of ATG-022 in Mainland of China and Australia. The Company continues to advance the clinical development of ATG-022 across different lines of gastric cancer treatment, including first-line therapy in combination with checkpoint inhibitors (CPIs) and chemotherapy (CAPOX/FOLFOX); second-line therapy in combination with CPIs; and third-line therapy as monotherapy, covering patients with varying levels of CLDN18.2 expression. In addition, the CLINCH study of ATG-022 includes a basket trial cohort evaluating multiple tumor types, with the majority of patients continuing to receive treatment.

2. Next-Generation ADCs and Proprietary TCEs

ATG-125 (B7-H3 × PD-L1 bispecific ADC): ATG-125 is an “IO+ADC ” dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation of immuno-oncology (IO) therapies. By simultaneously blocking B7-H3- and PD-L1-mediated immunosuppressive signaling, ATG-125 effectively activates T cells and induces immunological memory. Preclinical studies demonstrate that the bispecific ADC delivers superior in vivo efficacy compared with single-target B7-H3-ADC or PD-L1-ADC approaches. The Company plans to submit an IND for ATG-125 in Q1 2027.

TCE platform with steric hindrance masking technology: AnTenGager™ is Antengene’s proprietary, second-generation T cell engager (TCE) platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune diseases, solid tumors and hematological malignancies indications. Leveraging this platform, Antengene has discovered multiple investigational programs:

  • ATG-201 (CD19 x CD3 TCE): ATG-201 is a novel “2+1” CD19-targeted T-cell engager developed on the AnTenGager™ TCE platform for the treatment of B cell related autoimmune diseases. Preclinical data presented at the 2025 American College of Rheumatology (ACR) Annual Meeting showed that in non-human primate (NHP) models, the monkey surrogate of ATG-201 achieved deep and durable depletion of naïve B cells with a favorable safety profile, characterized by only a very mild and transient increase in cytokine levels. The IND-enabling study of ATG-201 has been completed and the IND-submission is under preparation.
  • ATG-106 (CDH6 x CD3 TCE): A global first-in-class CDH6 x CD3 targeted TCE being developed for the treatment of ovarian cancer and kidney cancer. The Company plans to submit an IND for ATG-106 in the first half of 2027.
  • ATG-112 (ALPPL2 x CD3 TCE): A global first-in-class ALPPL2 x CD3 targeted TCE being developed for the treatment of gynecologic tumor, non-small cell lung cancer, and pancreatic ductal adenocarcinoma. The Company has nominated a preclinical candidate (PCC) in January 2026.
  • Additional TCE programs for solid tumors: Antengene plans to submit an IND for ATG-110 (LY6G6D × CD3 TCE) in the first half of 2027 for the treatment of microsatellite-stable colorectal cancer. In addition, ATG-115 (an undisclosed bispecific antibody) and two undisclosed trispecific antibody programs are currently in preclinical development.

3. Innovative Treatment for Autoimmune Diseases: Globally First-in-Class ATG-207

ATG-207 is a globally first-in-class dual-function biologic being developed for the treatment of T cell–mediated autoimmune diseases. The Company plans to present the preclinical data for ATG-207 for the first time at an international scientific conference in 2026.

About Antengene

Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC) , ATG-037 (oral CD73 inhibitor) , ATG-101 (PD-L1 × 4-1BB bispecific antibody) , ATG-031 (CD24-targeting macrophage activator) , and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor) , is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com 

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com 

MOVA Launches Cleaning Solutions in Silicon Valley: Finding Answers for Premium Cleaning Through Pragmatic Innovation

By
Advertorial Desk
-

SAN JOSE, Calif., Jan. 16, 2026 /PRNewswire/ — Technology is no longer a distant, high-level concept, but something that truly serves users. At the M∞VA Universe integrated smart indoor technologies launch in Silicon Valley on January 15, 2026, MOVA demonstrated how its products solve real household needs through a connected ecosystem and practical business strategy.

MOVA
MOVA

A Technology Path Built Around Real Household Needs

Across its robot vacuums, wet and dry floor washers, and stick vacuums, MOVA’s product development starts with specific use scenarios. One example is the MOBIUS 60 robot vacuum, which introduces zone-specific cleaning to address concerns in premium homes about cross-contamination between different spaces. The system recognizes individual rooms and automatically returns to the dock to switch mop pads, helping prevent kitchen grease from being spread to bedrooms or living areas. This feature prioritizes practical hygiene over headline performance claims.

The same logic applies across the lineup. The X5 Ultra Steam Wet and Dry Vacuum uses Dual-Mode Steam & Hot-Water Spot-Spray Cleaning System to remove stubborn stains that are difficult to clean with traditional wet methods. The M50 Ultra is equipped with a Foldable & Extendable Handle, making it easier to clean under beds, sofas, and other low-clearance furniture. The G70 vacuum features Front Side Edge Cleaning  combined with a Robotic Arm, improving cleaning performance along edges and corners where dust commonly accumulates.

MOVA also extends this user-focused approach beyond floor care. The Aero C series hair dryers apply the company’s experience in airflow control and temperature management to personal care, focusing on stable performance and user comfort. The T1 Station window-cleaning robot uses hot water to improve cleaning results on outdoor glass surfaces, particularly in environments exposed to heavier dirt and weather conditions. To support this product strategy, MOVA embeds user insight teams within each product line, ensuring that design and engineering decisions remain closely connected to real-world usage.

Validation in Premium Markets

MOVA’s focus on what it describes as “effective innovation” has gained traction in competitive premium markets. During Black Friday 2025 in Southwest Europe, MOVA’s flagship robot vacuum—featuring live water mopping and a highly integrated automatic docking system—ranked among the top-selling products in the premium segment.

The company combine as broad online reach with offline credibility. MOVA products are available on major online platforms like Amazon. Partnership with local retailers, including BAUHAUS and MediaMarkt strengthen consumer trust. At the same time, collaboration with authoritative third-party reviewers provides professional validation and supports purchase decisions among premium markets.

Building a Sustainable Global Business

Beyond product performance, MOVA emphasizes long-term reliability. The company now serves more than 1.4 million households across over 60 countries and regions*. It also introduced a full-category three-year global warranty, directly addressing premium consumers’ expectations for durability and after-sales service.
MOVA’s global operations reflect a distributed approach to expertise. A French aesthetics center, a German innovation hub, and a Shanghai user experience center work together across design, engineering, and user research. Looking ahead to 2026, the company plans further global and offline expansion, while continuing to scale its user-driven innovation and quality control systems.

MOVA’s Silicon Valley launch marked a clear statement of intent. Rather than presenting a futuristic narrative, the company demonstrated how steady engineering, focused user insight, and disciplined global operations can define a credible premium position. In a market where many products appear increasingly similar, MOVA’s strategy suggests that true premium value comes from consistently improving real, everyday cleaning experiences through practical and thoughtful innovation.

*The company now serves more than 1.4 million households across over 60 countries and regions.(According to internal company data)

MOVA Unveils ‘the M∞VA Universe’ at Silicon Valley Launch, Positioning as a Global Premium AI Smart Living Leader

By
Advertorial Desk
-

SAN JOSE, Calif. , Jan. 16, 2026 /PRNewswire/ — MOVA,  a Global Premium AI Smart Living Leader, today hosted its global launch event, “M∞VA Universe”. The event marked a strategic declaration of the brand’s entry into the high-end global market, showcasing a cohesive ecosystem of intelligent cleaning solutions designed to redefine modern living. Beyond presenting groundbreaking products, MOVA aimed to demonstrate its deep technological prowess and scalable vision to a global audience of consumers and investors.

MOVA
MOVA

The “M∞VA Universe” symbolizes a boundaryless ecosystem where advanced AI, proprietary hardware, and user-centric design converge. This launch underscores MOVA’s commitment to building not just products, but an intelligent, interconnected, and self-improving living experience, highlighting its significant R&D investments and future growth trajectory.

Technological Pillars of the M∞VA Universe:

1. Autonomous Cleaning Hubs: Intelligence that Adapts

MOBIUS 60 with MopSwap™ Hub: Embodying the philosophy of “Precision Care by Zone, Purity Without Limits,” it features the revolutionary Space Hub Multi-Zone Mopping System. This intelligent system automatically switches between three dedicated mop types for specialized cleaning

Z60 Ultra Roller Complete: Revolutionizes wet cleaning with HydroForce Live Water Mopping and Mop Fluffing AI, ensuring constant cleanliness. Its MaxiReach System achieves complete edge-to-edge coverage. The integrated AutoShield™ Tech intelligently shields carpets from moisture during cleaning, while the StepMaster™ 2.0 system enables smarter navigation and obstacle crossing up to 8cm for seamless whole-home coverage.

MOVA X5 Ultra Steam: Features MOVA’s first* Dual-Mode Steam & Hot-Water Spot-Spray Cleaning System. It generates high-temperature steam for direct floor sanitization and deep cleaning, and can instantly mix steam with water to produce a hot-water spray that quickly dissolves dried stains for effective removal.

2. Ergonomic & Connected Cleaning Tools

M50 Ultra: As the world’s first* with an Easy Low Space Access Foldable & Extendable Handle, it enables lie-flat cleaning under furniture without bending over. The ergonomic Flex-Master™ Pro handle with a bionic wrist joint design allows flexible height adjustments and leverages natural arm motion to propel cleaning effortlessly, minimizing user strain.

MOVA G70 Cordless Vacuum: Features A Front Side Edge Cleaning with Robotic Arm for zero-blind-spot cleaning and Dual-Direction Dust Scraper Rings, showcasing thoughtful problem-solving through smart mechanics.

3. AI-Powered Personal Care: The Aero C Hair Dryer

Engineered with three core patents: a Dual-Airflow Boost System for efficiency, a Curved GlossFlow Chamber for enhanced styling, and C-Shaped Parallel Heating-Wire Technology for stable thermal output—each contributing to an intelligent, personalized care experience.

4. Intelligent High-Place Cleaning

N1 Window Cleaning Robot: A lightweight (1.3kg) AI-driven cleaner with smart path planning and 12-layer safety protocols for fully automated, reliable operation.

T1 Station with Portable Base: Introduces MOVA’s first* hot water cleaning and AI-powered seasonal water adjustment, representing a leap in outdoor cleaning intelligence and efficiency.

About MOVA

MOVA is a Global Premium AI Smart Living Leader dedicated to creating intelligent, integrated ecosystems that elevate everyday life. Through continuous innovation in AI, design, and engineering, MOVA is building the M∞VA Universe—a world where technology seamlessly fosters well-being, comfort, and effortless living.

*World’s First: From Frost & Sullivan, confirmed based on research on the global wet and dry vacuum cleaner market. This vacuum cleaner adopts a foldable and extendable robotic arm structure, allowing the handle to fold 90 degrees and adjust in length to accommodate users of different heights and various cleaning scenarios. The survey was completed in April 2025. Report NO: FS-2025-MPC-439377.

*MOVA Innovation / MOVA-pioneered technologies / MOVA’s groundbreaking technologies / MOVA first: These terms refer exclusively to product upgrades, functional enhancements or technological improvements compared to previous generations of MOVA products, and do not imply any comparison with products from other manufacturers.The right of interpretation shall vest in MOVA.

Final Entry Deadline in 2026 Asia-Pacific Stevie® Awards Extended to 30 January

By
Advertorial Desk
-

Stevie-winners to be celebrated at a ceremony in Macau on 17 April

FAIRFAX, Va. , Jan. 16, 2026 /PRNewswire/ — The Stevie® Awards, organizer of the world’s premier business awards programs, announced that they have revised the schedule for the 2026 (13th annual) Asia-Pacific Stevie® Awards.

By popular demand, the final entry deadline has been extended to 30 January. The judging process will extend through 6 February. Gold, Silver, and Bronze Stevie Award winners will be announced on 12 February. Winners will be celebrated during an awards ceremony on 17 April at the Venetian Hotel in Macau.

The Asia-Pacific Stevie Awards is the only business awards program to recognize innovation throughout the entire Asia-Pacific region. The competition is open to all organizations across 29 markets of the Asia-Pacific region: large and small, for-profit and non-profit, public and private.

The awards focus on recognizing innovation in all its forms, wherever it is achieved in the workplace. Entries will be accepted in 30+ languages in the following awards category groups:

All organizations that are honored with Gold, Silver, or Bronze Stevie Award trophies in the Company/Organization categories will automatically be included in voting for the People’s Choice Stevie® Awards for Favorite Companies. People’s Choice winners will receive a special People’s Choice Stevie Award trophy, giving honorees in the Company/Organization categories the opportunity to receive a second award, as voted by the general public worldwide. Voting for the People’s Choice Stevie Awards for Favorite Companies will open on 16 February and go through 13 March.

Scores of professionals from throughout the region will participate in the judging process to determine the Gold, Silver, and Bronze Stevie Award winners.

Some of the Asia-Pacific region’s most innovative organizations won Asia-Pacific Stevie Awards in 2025, including AstraZeneca Philippines (Philippines), Ayala Land, Inc. – Makati Development Corporation (Philippines), Cathay Financial Holdings Co., Ltd. (Taiwan region), City of Sydney (Australia), CK Hutchison Holdings Limited (Hong Kong SAR), Coca-Cola Bottlers Japan Holdings Inc. (Japan), DigiPlus Interactive Corp. (Philippines), Dong-A Pharmaceutical Co. (Korea), Eastern Communications (Philippines), Extendmax Vietnam Company Limited (Vietnam), Generali Hong Kong (Hong Kong SAR), HP (Greater Asia) (Singapore), IBM Singapore (Singapore), IntouchCX (India), Kacific Broadband Satellites Group (Singapore), Link Asset Management Limited (Hong Kong SAR), Metro Pacific Investments Corporation (Philippines), Ooredoo Maldives (Maldives), PJ Lhuillier Inc. (Philippines), PLDT and Smart (Philippines), PT Pertamina (Persero) (Indonesia), SM Supermalls (mainland China), and Wolters Kluwer Tax & Accounting Asia Pacific (Australia).

About the Stevie Awards
Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, the Stevie Awards for Sales & Customer Service, and the newest Stevie Awards program, the Stevie Awards for Technology Excellence. Stevie Awards competitions receive over 12,000 entries annually from organizations in more than 70 nations and territories. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

PR Newswire Asia is the official news release distribution partner of the 2026 Asia-Pacific Stevie Awards.

 

Hugel accelerates global value creation with U.S.-led growth strategy

By
Advertorial Desk
-

– President and Global CEO Carrie Strom outlines mid-term growth strategy including global vision, U.S. channel strategy, and portfolio expansion
– Hugel targets KRW900 billion in total net sales and 30% of sales from U.S. by 2028

SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ — Hugel, Inc., a leading global medical aesthetics company publicly traded in South Korea, has outlined its vision to transform from the leading Korean toxin company into a leader in global aesthetics. Having firmly established the presence of K-aesthetics in the U.S., the world’s largest botulinum toxin market, the company will increase investment in the critical U.S. market, including the introduction of a hybrid sales model later this year. This strategy is aimed at expanding customer adoption and enhancing profitability.

Carrie Strom, Global CEO of Hugel, presents at the J.P. Morgan Healthcare Conference on January 15
Carrie Strom, Global CEO of Hugel, presents at the J.P. Morgan Healthcare Conference on January 15

Hugel unveiled the plans while presenting at the Asia-Pacific track of the J.P. Morgan Healthcare Conference held in San Francisco on January 15. The annual conference is the world’s largest healthcare investment symposium, bringing together global pharmaceutical and biotech companies to share industry trends and business strategies.

“As we build the U.S. operation and increase our strategic investments globally, we are targeting KRW900 billion in annual net sales by 2028, with the U.S. representing more than 30% of the global revenue mix. A critical part of the plan is our innovative U.S. hybrid sales model, which enhances our partnership with our U.S. distributor while also introducing a direct sales team. This model, focused on clear customer segmentation and alignment, will allow us to expand breadth and depth while delivering attractive operating margins,” Hugel’s President and Global CEO Carrie Strom said during the presentation.

Following U.S. FDA approval in 2024, Hugel started sales of its botulinum toxin product in the U.S. last year through its local partner BENEV. Starting later this year, Hugel will adopt a hybrid sales approach, operating both partner-led distribution and direct sales. Under this strategy, Hugel aims to substantially enhance profitability while achieving robust revenue growth. The company targets a 10% market share in the U.S. by 2028 and 14% by 2030.

In addition to the U.S. commercial strategy, Hugel is also focusing on expanding its product portfolio in key markets like Korea and the U.S. to create synergies with its flagship offerings. The company will pursue strategic business development initiatives such as in-licensing and co-promotion. These efforts are aimed at addressing growing demand in the skin booster segment and building an aesthetics portfolio optimized for global markets.

“By expanding our global market share with a strong focus on the U.S., we will accelerate Hugel’s global business transformation and drive revenue growth through tangible outcomes such as portfolio optimization. We also remain firmly committed to maintaining a solid financial structure, including securing industry-leading operating profits,” Strom added.

About Hugel

Established in 2001, Hugel is a global leader in medical aesthetics, specializing in the production of injectables for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters, as well as absorbable sutures and cosmetic products. With a proven track record of safety and quality, Hugel is deeply committed to advancing the industry through robust medical affairs, comprehensive training programs, and dynamic industry forums.

Over the past 20 years, the company has built a presence in approximately 70 countries and operates nine global subsidiaries across the U.S., Australia, Canada, Taiwan, China, Hong Kong, Singapore, and Thailand. Leveraging strong industry momentum, Hugel is well-positioned for continued growth and market expansion worldwide.

Contact:
Jihyun Kim, Manager of the PR Team, Hugel
jihyun.kim@hugel-inc.com 

 

1...1,2741,2751,276...6,473Page 1,275 of 6,473